Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Cardiology
•
Cardio-Rheumatology
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Related Questions
What would be the minimum duration of IL-1 therapy you would recommend for chronic pericarditis?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How do you approach management of recurrent idiopathic pleuropericarditis?
How do you approach management of RA in patients who have developed anti-drug antibodies to infliximab, especially if use of methotrexate is contraindicated and patients have tried and failed several other biologics?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
How do you approach the use of immunosuppressive therapy in patients with rheumatoid arthritis and underlying immunodeficiency, such as IgA deficiency?
How do you approach dyspnea in a patient with seropositive rheumatoid arthritis with normal imaging findings but abnormal PFT findings (restriction, reduced DLCO)?
How would you approach using the new vagus nerve stimulator for patients with RA?
